Product Ref: PFACE01 Category: A
Royal Mail 2nd Class / Parcel Force 48
UK to UK :Normally arrives in 2-4 business days.
UK to Ireland :Normally arrives in 4-6 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage
----------------------------------------------------------------------------------------------------------------
Royal Mail First Class / Parcel Force 24
UK to UK :Normally arrives in 1-2 business days.
UK to Ireland 3-4 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note :Trackable , Royal Mail insured up to £50.
--------------------------------------------------------------------------------------------------------
Parcel Force Express AM Guaranteed before Midday.
UK to UK only . UP to 5KG Max Weight
Arrives next day before 12 noon, requires a signature.
Parcel Forcel Terms & Conditions apply
Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.
| Category | POM-V |
| Temperature | Ambient |
| MA/VM/EU No: | 31592/4005 |
| Species |
|
| VMD Link | Product Information Database (defra.gov.uk) |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-456396 |
| Dosage | For intramuscular use. Treatment of ovarian follicular cysts 100-150 micrograms of gonadorelin (as acetate) per animal (i.e. 2- 3 ml of the product per animal). If necessary, treatment can be repeated at intervals of 1-2 weeks. In association with artificial insemination to optimise the time of ovulation, improving the chances that the treated cow will become fertile 100 micrograms of gonadorelin (as acetate) per animal (i.e. 2 ml of the product per animal). It must be administered at the same time as artificial insemination and/or 12 days after this. The following timing of injection and insemination should be followed: •Injection should be performed between 4 and 10 hours after oestrus detection. •An interval of at least 2 hours between the injection of GnRH and artificial insemination is recommended. •Artificial insemination should be carried out in accordance with the usual field recommendations, i.e., 12 to 24 hours after oestrus detection. Induction and synchronisation of oestrus and ovulation in combination with prostaglandin F2α (PGF2α) with or without progesterone as part of Fixed Time Artificial Insemination (FTAI) protocols The following FTAI protocols have been commonly reported in the literature: In cycling cows: •Day 0: Inject 100 micrograms of gonadorelin (as acetate) per animal (2 ml of the product) •Day 7: Inject PGF2α or analogue (luteolytic dose) •Day 9: Inject 100 micrograms of gonadorelin (as acetate) per animal (2 ml of the product) •Artificial insemination 16–20 hours later, or at observed oestrus if sooner. Alternatively: •Day 0: Inject 100 micrograms of gonadorelin (as acetate) per animal (2 ml of the product) •Day 7: Inject PGF2α or analogue (luteolytic dose) •Artificial insemination and injection of 100 micrograms of gonadorelin (as acetate) per animal (2 ml of the product) 60–72 hours later, or at observed oestrus if sooner. In cycling and non-cycling cows and heifers: •Insert intravaginal progesterone releasing device for 7-8 days. •Inject 100 micrograms of gonadorelin (as acetate) per animal (2 ml of the product) at progesterone device insertion. •Inject a luteolytic dose of PGF2α or analogue 24 hours prior to device removal. •FTAI 56 hours after removal of the device, or •Inject 100 micrograms of gonadorelin (as acetate) per animal (2 ml of the product) 36 hours after progesterone releasing device removal and FTAI 16 to 20 hours later. |
| Withdrawals | Do not use in animals with known hypersensitivity to gonadorelin and to any excipient. Do not use for shortening of oestrus during infectious diseases and other relevant disorders. In the treatment of cystic ovaries, the condition of ovarian follicular cysts should be diagnosed by rectal palpation revealing the presence of persisting follicular structures with a diameter over 2.5 cm and should be confirmed by the use of plasma or milk progesterone assay. The product should be administered at least 14 days after calving due to the absence of receptivity of the hypophysis before that time. For induction and synchronisation of oestrus and ovulation in Fixed Time Artificial Insemination (FTAI) protocols, the product should be administered at least 35 days after calving. The response of cows and heifers to synchronisation protocols is influenced by the physiological state at the time of treatment. Responses to treatment can vary either across herds or across cows within herds. However, the percentage of cows displaying oestrus within a given period is usually greater than in untreated cows and the subsequent luteal phase is of normal duration. For protocol that only includes PGF2α recommended for cycling cows: To maximise conception rates of cows to be treated, the ovarian status should be determined and regular cyclic ovarian activity confirmed. Optimal results will be achieved in healthy normally-cycling cows. Animals in poor condition, whether from illness, inadequate nutrition or other factors, may respond poorly to treatment. Not indicated for use during pregnancy. Can be used during lactation. At up to 5 times the recommended dose and in a regimen extended from one to three daily administrations, no measurable signs of either local or general clinical intolerance were observed. A synergistic effect occurs in case of combined administration of FSH. Withdrawal period Meat and offal: zero days. Milk: zero hours. User warnings Care should be taken when handling the product to avoid self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Care should be taken to avoid skin and eye contact. In case of skin contact, rinse immediately and thoroughly with water as GnRH analogues can be absorbed through the skin. In case of accidental contact with eyes, rinse thoroughly with plenty of water. The effects of accidental exposure in pregnant women or in women with normal reproductive cycles are unknown; therefore it is recommended that pregnant women should not administer the product, and that women of child-bearing age should administer the product with caution. People with known hypersensitivity to GnRH analogues, should avoid contact with the veterinary medicinal product. |
